CORONA Remedies

CORONA · NSE

— · —

₹2,098.8

Closing price — 31 Jul 2026

Market cap ₹12,845 Cr · EPS ₹13.89

Valuation

Blended fair value using DCF and peer comparison methods.

Intrinsic Value

₹584

-72.2% vs ₹2,099

Overvalued

UndervaluedFair valueOvervalued

DCF

₹161

Peer methods

₹1,008

Intrinsic value

₹584

DCF discounts future cash flows to present value. Peer methods compare against sector multiples. Averaging both reduces the limitations of each method alone.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
CORONA Remedies CORONA · you	₹12,845 Cr	70.5×	17.5×	—	24.8%	13.2%	16.6%
Sector median	—	36.1×	7.4×	28.3×	20.1%	17.7%	14.4%
Abbott India ABBOTINDIA	₹55,558 Cr	35.7×	11.6×	29.4×	32.5%	22.4%	9.0%
Ipca Laboratories IPCALAB	₹41,806 Cr	36.3×	5.1×	22.4×	14.2%	11.8%	15.6%
Gland Pharma GLAND	₹37,695 Cr	36.8×	3.6×	23.5×	9.9%	16.0%	21.1%
Glaxosmithkline Pharmaceuticals GLAXO	₹37,177 Cr	35.9×	16.4×	28.3×	45.7%	27.1%	5.5%
Emcure Pharmaceuticals EMCURE	₹33,796 Cr	35.8×	6.7×	19.9×	18.7%	10.0%	15.4%
Wockhardt WOCKPHARMA	₹30,662 Cr	144.1×	6.2×	59.0×	4.3%	6.3%	8.4%
Ajanta Pharmaceuticals AJANTPHARM	₹27,006 Cr	34.9×	8.1×	28.3×	23.3%	19.4%	13.4%
Acutaas Chemicals ACUTAAS	₹26,189 Cr	73.8×	15.8×	54.5×	21.5%	26.6%	29.5%

Peer comparison verdict

CORONA trades at a premium to peers (P/E 70.5× vs median 36.1×), but its higher ROE of 24.8% (sector 20.1%) justifies much of that premium — quality rarely comes cheap.

Business quality

Valuation

P/E ratio

70.5×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

24.8%

ROCE

28.1%

ROA

—

Growth

Revenue CAGR (3yr)

16.6%

EPS CAGR (3yr)

29.7%

Efficiency

Asset turnover

—

FCF yield

0.4%

Dividend yield

0.5%

Liquidity & Solvency

Debt / Equity

0.17×

Debt / EBITDA

—

Interest coverage

76.3×

Current ratio

0.96×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹1,403 Cr

Net profit

₹185 Cr

Operating margin

—

Net margin

13.2%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

₹229.48 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

₹55.35 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹127 Cr

Equity

₹747 Cr

Debt / Equity

0.17×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

69.0%

FII

2.3%

+0.4 pp QoQ

DII

7.0%

+0.3 pp QoQ

Retail

21.8%

Trend over time (%)

Quarterly data

Category	Dec 2025	Mar 2026	Change (YoY)
Promoter	69.0%	69.0%	0.0 ppvs oldest
FII (Foreign)	1.8%	2.3%	+0.4 ppvs oldest
DII (Domestic)	6.8%	7.0%	+0.3 ppvs oldest
Retail	22.4%	21.8%	-0.7 ppvs oldest

Signals from the trend

➡️

PromoterStable — no notable buying or selling

➡️

FIIStable

➡️

DIIStable

Shareholding pattern has been broadly stable — no strong signals in either direction.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.